Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet
Inflammation is a new hallmark feature of cancer initiation and progression. We aimed to investigate the association between inflammatory response biomarkers and progression-free survival and overall survival in advanced lung adenocarcinoma patients treated with first-line pemetrexed and platinum do...
Saved in:
| Main Authors: | Yanjuan Xiong, Ning Zhao, Yu Zheng, Jian Wang, Feng Wei, Xiubao Ren |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-05-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317701639 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
by: Sae Wada, et al.
Published: (2012-01-01) -
Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma
by: L. Yu. Vladimirova, et al.
Published: (2021-03-01) -
The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database
by: Shun Li, et al.
Published: (2025-04-01) -
Establishment and Genetic Profiling of Platinum/Taxane Doublet-Resistant Cells Generated by Hybridizing Single Resistant Cells
by: Seiji Isonishi, et al.
Published: (2022-09-01) -
A rare presentation of the diffuse dermal mucinosis in adenocarcinoma of the lungs treated with pembrolizumab and pemetrexed
by: Karen Koch, MBChB (UCT), FCDerm (SA), FRACP, MMed (Derm), et al.
Published: (2025-07-01)